Midlothian, VA 23114, US
Biotechnology
www.VaNeuropsychiatry.org
The Virginia Institute of Neuropsychiatry (VIN) is dedicated to the understanding and treatment of patients with neuropsychiatric disorders, including traumatic brain injury. VIN developed NeuroGage®, software for tracking brain MRI volume change.
The Virginia Institute of Neuropsychiatry (VIN) is dedicated to the understanding and treatment of patients with neuropsychiatric disorders, including traumatic brain injury. Founded in 2001 by David E. Ross, M.D., VIN provides clinical and forensic services to its patients, and education for doctors and students. Since 2010, VIN has been pioneering the application of NeuroQuant®, FDA-cleared software for measuring MRI brain volume, to patients with mild to moderate traumatic brain injury (TBI). NeuroQuant® has been a major breakthrough in structural brain imaging by automating brain volume try and drastically reducing the time needed for analysis. VIN developed NeuroGage® to extend the utility of NeuroQuant® in several ways, including longitudinal (change over time) analysis, which is critically important for understanding the effects of trauma on the brain. Since 2012, VIN has published 10 peer-reviewed articles in this field. NeuroQuant® and NeuroGage® are extremely valuable for providing objective evidence of brain injury in patients with mild to moderate traumatic brain injury (TBI). NeuroQuant® and NeuroGage® have been admitted successfully as evidence in 3 court cases, including federal court, with no failures to be admitted. They have been estimated to increase the settlement value of legal cases involving patients with mild to moderate TBI by approximately $100,000 each. Cost is approximately $2200 or less, include 2 brain MRIs (often covered by insurance), and 2 sets of NQ/NG analyses (time 1 MRI, time 2 MRI, and t1-t2 longitudinal analysis). Therefore, these software devices provide an excellent value proposition for patients and their attorneys. This business model has been very successful with Dr. Ross’s patients at VIN. In order to scale up the business model to include the majority of patients with mild to moderate TBI involved with legal cases, NeuroGage® needs to become FDA-cleared and be marketed on a national scale.
NeuroGage® is a software device designed to understand the effects of trauma or disease on the brain. It allows for longitudinal (change over time) analysis, which is critically important for understanding the effects of trauma on the brain. NeuroGage® is extremely valuable for proving brain injury in patients with mild to moderate traumatic brain injury (TBI). NeuroQuant® and NeuroGage® have been admitted successfully as evidence in 3 court cases, including federal court, with no failures to be admitted. These software devices provide an excellent value proposition for patients and their attorneys. This business model has been very successful with Dr. Ross’s patients at VIN. In order to scale up the business model to include the majority of patients with mild to moderate TBI involved with legal cases, NeuroGage® needs to become FDA-cleared and be marketed on a national scale.
Prior Year Revenue | Current Year Revenue | Next Year Revenue |
---|---|---|
Sign up as Investor | Sign up as Investor | Sign up as Investor |
Company Age | Employees | Sub-Industry |
---|---|---|
15 years, 7 months | 0 | Biotechnology – Devices & Equipment |
Company Type | Stock Exchange | Stock Symbol |
---|---|---|
Privately-Held | – | – |